Qiagen NV (QGEN) Actualités

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

Ingenuity Pathway Analysis Interpret extends analysis capabilities of human-curated knowledge base with AI technology AI-extension highlights...

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

EZ2 Connect for automated nucleic acid purification has reached over 1,000 placements worldwide, contributing to a global installed base of more...

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment Site in Esplugues de...

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

Venlo, the Netherlands, Nov. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two...

QIAGEN collaborates with McGill University to advance microbiome research

Montreal, Canada, and Venlo, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

Venlo, the Netherlands, Nov. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for...

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

Germantown, Maryland, and Venlo, the Netherlands, Nov. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today...

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment

Germantown, Maryland, and Venlo, the Netherlands, Oct. 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications

Venlo, the Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced key updates to its...

QIAGEN N.V. to release results for Q3 2024 and hold webcast

Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release...